298 related articles for article (PubMed ID: 20392606)
1. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction.
Matsumoto K; Takeshita A; Ikawa K; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2010 Aug; 36(2):179-81. PubMed ID: 20392606
[TBL] [Abstract][Full Text] [Related]
2. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
[TBL] [Abstract][Full Text] [Related]
3. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.
Stalker DJ; Jungbluth GL; Hopkins NK; Batts DH
J Antimicrob Chemother; 2003 May; 51(5):1239-46. PubMed ID: 12668582
[TBL] [Abstract][Full Text] [Related]
6. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency.
Lin YH; Wu VC; Tsai IJ; Ho YL; Hwang JJ; Tsau YK; Wu CY; Wu KD; Hsueh PR
Int J Antimicrob Agents; 2006 Oct; 28(4):345-51. PubMed ID: 16935472
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction.
Tsuji Y; Hiraki Y; Matsumoto K; Mizoguchi A; Kobayashi T; Sadoh S; Morita K; Kamimura H; Karube Y
J Infect Chemother; 2011 Feb; 17(1):70-5. PubMed ID: 20582446
[TBL] [Abstract][Full Text] [Related]
8. Linezolid-associated thrombocytopenia.
Lam S
Consult Pharm; 2012 Jul; 27(7):504-8. PubMed ID: 22910131
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of linezolid.
French G
J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii45-53. PubMed ID: 12730142
[TBL] [Abstract][Full Text] [Related]
10. Renal function as a predictor of linezolid-induced thrombocytopenia.
Matsumoto K; Takeda Y; Takeshita A; Fukunaga N; Shigemi A; Yaji K; Shimodozono Y; Yamada K; Ikawa K; Morikawa N
Int J Antimicrob Agents; 2009 Jan; 33(1):98-9. PubMed ID: 18790615
[No Abstract] [Full Text] [Related]
11. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin.
Hiraki Y; Tsuji Y; Matsumoto K; Morita K; Kamimura H; Karube Y
Am J Med Sci; 2011 Dec; 342(6):456-60. PubMed ID: 21681075
[TBL] [Abstract][Full Text] [Related]
12. Hematologic effects of linezolid in young children.
Meissner HC; Townsend T; Wenman W; Kaplan SL; Morfin MR; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S186-92. PubMed ID: 14520145
[TBL] [Abstract][Full Text] [Related]
13. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.
Wu VC; Wang YT; Wang CY; Tsai IJ; Wu KD; Hwang JJ; Hsueh PR
Clin Infect Dis; 2006 Jan; 42(1):66-72. PubMed ID: 16323094
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients.
Hirano R; Sakamoto Y; Tachibana N; Ohnishi M
Int J Clin Pharm; 2014 Aug; 36(4):795-9. PubMed ID: 24913359
[TBL] [Abstract][Full Text] [Related]
15. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.
Alffenaar JW; Kosterink JG; van Altena R; van der Werf TS; Uges DR; Proost JH
Ther Drug Monit; 2010 Feb; 32(1):97-101. PubMed ID: 20042919
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
[TBL] [Abstract][Full Text] [Related]
17. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.
Nasraway SA; Shorr AF; Kuter DJ; O'Grady N; Le VH; Cammarata SK
Clin Infect Dis; 2003 Dec; 37(12):1609-16. PubMed ID: 14689341
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic evaluation of linezolid in patients with major thermal injuries].
Le Floch R; Arnould JF; Vinsonneau C; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Lovering AM
Pathol Biol (Paris); 2010 Apr; 58(2):e27-31. PubMed ID: 19854590
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.
Soriano A; Ortega M; García S; Peñarroja G; Bové A; Marcos M; Martínez JC; Martínez JA; Mensa J
Antimicrob Agents Chemother; 2007 Jul; 51(7):2559-63. PubMed ID: 17470658
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytopenia associated with linezolid therapy.
Attassi K; Hershberger E; Alam R; Zervos MJ
Clin Infect Dis; 2002 Mar; 34(5):695-8. PubMed ID: 11803505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
